 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SBT6290 / ARS Pharma
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (clinicaltrials.gov) - Apr 11, 2022
P1/2, N=0, Withdrawn, Sponsor: Silverback Therapeutics
N=225 --> 0 | Trial completion date: May 2025 --> Mar 2022 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2025 --> Mar 2022
- |||| SBT6290 / ARS Pharma
Enrollment open, Combination therapy, Metastases: A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (clinicaltrials.gov) - Mar 4, 2022
P1/2, N=225, Recruiting, Sponsor: Silverback Therapeutics
N=225 --> 0 | Trial completion date: May 2025 --> Mar 2022 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2025 --> Mar 2022 Not yet recruiting --> Recruiting
- ||||| SBT6290 / ARS Pharma
New P1/2 trial, Combination therapy, Metastases: A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (clinicaltrials.gov) - Feb 9, 2022
P1/2, N=225, Not yet recruiting, Sponsor: Silverback Therapeutics
- SBT8230 / Silverback Therap, SBT6290 / Silverback Therap, SBT6050 / Silverback Therap
[VIRTUAL] Immunomodulatory Antibody Conjugates for the Treatment of Cancer & Chronic Viral Infections () - Sep 23, 2021 - Abstract #ADCUSA2021ADC_USA_157;
Not yet recruiting --> Recruiting Synopsis An overview of Silverback’s ImmunoTAC (Immunomodulatory Targeted Antibody Conjugate) technology platform Discussing the discovery and development of ImmunoTAC molecules containing a TLR8 agonist payload designed to stimulate local activation of myeloid cells Examining how broad and versatile potential of the ImmunoTAC platform is exemplified by oncology (SBT6050 and SBT6290) and virology (SBT8230) development candidates
- |||| SBT6290 / Silverback Therap
Nectin4 is nectar, just ask Nectin Therapeutics, and these guys at $SBTX 1858 - SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells #AACR21 Silverback Therapeutics (Twitter) - Apr 7, 2021
- SBT6290 / Silverback Therap
[VIRTUAL] SBT6290, a systemically administered Nectin4-directed TLR8 ImmunoTAC™ product candidate, is designed for tumor-localized activation of myeloid cells () - Mar 11, 2021 - Abstract #AACR2021AACR_3306;
Systemic administration of a SBT6290 surrogate in mice bearing Nectin4-expressing tumors results in intra-tumoral myeloid and T cell activation and increased overall survival. The preclinical data described here demonstrate the potential for SBT6290 to drive anti-tumor responses and support continued preclinical development of SBT6290 for Nectin4-expressing tumors.